Sign in

    Nicholas Econom

    Research Analyst who most recently worked at Raymond James

    Nicholas Econom is a Research Analyst who most recently worked at Raymond James & Associates, specializing in equity research with a focus on healthcare and biotechnology companies. While at Raymond James, he covered a range of notable firms within the life sciences sector, earning a reputation for insightful stock calls supported by industry recognition and collaboration with high-profile transactions. His career began prior to Raymond James, and as of 2025, he has transitioned to Cantor Fitzgerald & Co., continuing his analyst work in similar sectors. Econom holds recognized industry credentials and is registered with FINRA, maintaining active securities licenses essential for equity research roles.

    Nicholas Econom's questions to Wave Life Sciences (WVE) leadership

    Nicholas Econom's questions to Wave Life Sciences (WVE) leadership • Q1 2025

    Question

    Nicholas Econom of Cantor Fitzgerald inquired about the lung tissue distribution profile of Wave's AIMers and whether the company remains confident in a semi-annual or annual dosing strategy for its INHBE program, given a competitor is targeting quarterly dosing.

    Answer

    Chief Scientific Officer Dr. Erik Ingelsson explained that lung distribution is achieved through PN chemistry optimization, not a conjugate. President and CEO Dr. Paul Bolno expressed high confidence in their less frequent dosing strategy for the INHBE program. He cited preclinical data published in NAR showing their siRNA format has 30-fold superior AGO2 loading, which translates to greater potency and durability compared to competitor platforms.

    Ask Fintool Equity Research AI

    Nicholas Econom's questions to Apellis Pharmaceuticals (APLS) leadership

    Nicholas Econom's questions to Apellis Pharmaceuticals (APLS) leadership • Q3 2024

    Question

    Nicholas Econom, on behalf of Steve Seedhouse at Raymond James, asked about potential future renal indications for pegcetacoplan and the timeline for announcing further clinical development plans in nephrology.

    Answer

    CEO Dr. Cedric Francois provided a direct response, stating that while they are not ready to announce specific plans yet, they are actively working on it and expect to provide more clarity on their nephrology pipeline expansion in the coming months.

    Ask Fintool Equity Research AI

    Nicholas Econom's questions to Editas Medicine (EDIT) leadership

    Nicholas Econom's questions to Editas Medicine (EDIT) leadership • Q2 2024

    Question

    Nicholas Econom, on for Steve Seedhouse, asked about the demand for fertility support in Editas' own trials and the potential market impact if commercial coverage is denied.

    Answer

    Chief Medical Officer Baisong Mei confirmed fertility support is critical and provided in their trials. Chief Commercial and Strategy Officer Caren Deardorf added that she does not anticipate a huge market impact, as the CMMI model for Medicaid patients includes a carve-out for fertility preservation and commercial plans are unaffected by the recent negative HHS opinion.

    Ask Fintool Equity Research AI